Will DOTS do it? A reappraisal of tuberculosis control in countries with high rates of HIV infection

International Journal of Tuberculosis and Lung Disease

Volumn 3, Issue 6, 1999, Pages 457-465

  De Cock, Kevin M ^a   Chaisson, R E ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; RIFAMPICIN; TUBERCULIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; DRUG RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MYCOBACTERIUM TUBERCULOSIS; POPULATION DYNAMICS; PRIORITY JOURNAL; SPUTUM ANALYSIS; TUBERCULOSIS; TUBERCULOSIS CONTROL;

AFRICA; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ALASKA; BALTIMORE; COMMUNICABLE DISEASE CONTROL; COMORBIDITY; CROSS INFECTION; DEVELOPING COUNTRIES; DISEASE OUTBREAKS; DISEASE TRANSMISSION, HORIZONTAL; FEMALE; HUMANS; MALE; NEW YORK CITY; POPULATION DYNAMICS; PREVALENCE; PROGRAM EVALUATION; RISK FACTORS; TUBERCULOSIS, PULMONARY; UNITED STATES; WORLD HEALTH ORGANIZATION;

EID: 0032973632     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Nakajima H. Tuberculosis: a global emergency. World Health 1993; 46th Year, no 4, July-August, Geneva, Switzerland: World Health Organization, 1993.
2. De Cock K M, Soro B, Coulibaly I M, Lucas S B. Tuberculosis and HIV infection in sub-Saharan Africa. JAMA 1992; 268: 1581-1587.
3. Raviglione M C, Harries A D, Msiska R, Wilkinson D, Nunn P. Tuberculosis and HV: current status in Africa. AIDS 1997; 11 (Suppl B): S115-S123.
4. Cantwell M F, Binkin N J. Tuberculosis in sub-Saharan Africa: a regional assessment of the impact of the human immunodeficiency virus and National Control Programme quality. Tubercle Lung Dis 1996; 77: 220-225.
5. Harries A D, Mbewc L N, Salaniponi F M L, et al. Tuberculosis programme changes and treatment outcomes in patients with smear-positive pulmonary tuberculosis in Blantyre, Malawi. Lancet 1996; 347: 807-809.
6. Chum H J, O'Brien R J, Chonde T M, Graf P, Rieder H L. An epidemiological study of tuberculosis and HIV infection in Tanzania, 1991-1993. AIDS 1996; 10: 299-309.
7. Harries A D, Parry C, Mbewe L N, et al. The pattern of tuberculosis in Queen Elizabeth Central Hospital, Blantyre, Malawi: 1986-1995. Int J Tuberc Lung Dis 1997; 1: 346-351.
8. Cantwell M F, Binkin N J. Impact of HIV on tuberculosis in sub-Saharan Africa: a regional perspective. Int J Tuberc Lung Dis 1997; 1: 205-214.
9. Styblo K. Epidemiology of tuberculosis. Selected Papers. The Hague, The Netherlands: Royal Netherlands Tuberculosis Association, 1991.
10. Bayer R, Wilkinson D. Directly observed therapy for tuberculosis: history of an idea. Lancet 1995; 345: 1545-1548.
11. Frieden T R, Fujiwara P I, Washko R M, Hamburg M A. Tuberculosis in New York City - turning the tide. N Engl J Med 1995; 333: 229-233.
12. World Health Organization. Framework for Effective Tuberculosis Control. Geneva, Switzerland: World Health Organization, 1994.
13. Global Tuberculosis Programme. Treatment of Tuberculosis: Guidelines for National Programmes. Geneva, Switzerland: World Health Organization, 1997.
14. Yanai H, Uthaivoravit W, Panich V, et al. Rapid increase in HIV-related tuberculosis, Chiang Rai, Thailand, 1990-1994. AIDS 1996; 10: 527-531.
15. Richards S B, St Louis M, Nieburg P, et al. Impact of the HIV epidemic on tuberculosis in Abidjan, Côte d'Ivoire. Tubercle Lung Dis 1995; 76: 11-16.
16. Kleinschmidt I, Churchyard G. Variation in incidence of tuberculosis in subgroups of South African gold miners. Occup Environ Med 1997; 54: 636-641.
17. Kumaresan J A, Maganu E T. Case holding in patients with tuberculosis in Botswana. BMJ 1992; 305: 340-341.
18. Kenyon T A, Mwasekaga M J, Huebner R, Rumisha D, Binkin N, Magann E. Low levels of drug resistance amidst rapidly increasing tuberculosis and human immunodeficiency virus coepidemics in Botswana. Int J Tuberc Lung Dis 1999; 3: 4-11.
19. WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Anti-tuberculosis drug resistance in the world. Geneva, Switzerland: World Health Organization, 1997.
20. Chaisson R E, Clermont H C, Holt E, et al. Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection. Am J Respir Clin Care Med 1996; 154: 1034-1038.
21. Wilkinson D. High compliance tuberculosis treatment programme in a rural community. Lancet 1994; 343: 647-648.
22. De Cock K M, Wilkinson D. Tuberculosis control in resource poor countries: novel approaches in the era of HIV. Lancet 1995; 346: 675-677.
23. De Cock K M. Tuberculosis control in resource-poor settings with high rates of HIV infection. Am J Public Health 1996; 86: 1071-1073.
24. Elliott A M, Foster S D. Thiacetazone: time to call a halt? Considerations on the use of thiacetazone in African populations with a high prevalence of human immunodeficiency virus infection. Tubercle Lung Dis 1996; 77: 27-29.
25. Rieder H L, Enarson D A. Rebuttal: time to call a halt to emotions in the assessment of thioacetazone. Tubercle Lung Dis 1996; 77: 109-111.
26. Lucas S B, Hounnou A, Peacock C, et al. The mortality and pathology of HIV infection in a West African city. AIDS 1993; 7: 1569-1579.
27. Ackah A N, Coulibaly D, Digbeu H, et al. Response to treatment, mortality, and CD4 lymphocyte counts in HIV-infected persons with tuberculosis in Abidjan, Ivory Coast. Lancet 1995; 345: 607-610.
28. Greenberg A E, Lucas S B, Tossou O, et al. Autopsy-proven causes of death in HIV-infected patients treated for tuberculosis in Abidjan, Côte d'Ivoire. AIDS 1995; 9: 1251-1254.
29. Grant A D, Djomand G, Smets P, et al. Profound immunosuppression across the spectrum of opportunistic disease among hospitalized HIV-infected adults in Abidjan, Côte d'Ivoire. AIDS 1997; 11: 1357-1364.
30. Wiktor S Z, Sassan-Morokro M, Grant A D, et al. Randomized clinical trial of cotrimoxazole chemoprophylaxis to reduce morbidity and mortality in HIV-infected tuberculosis patients in Abidjen, Côte d'Ivoire. Lancet (in press).
31. Harries A D, Maher D. TB/HIV. A clinical manual. Geneva, Switzerland: World Health Organization, 1996.
32. Nyangulu D S, Harries A D, Kang'ombe C, et al. Tuberculosis in a prison population in Malawi. Lancet 1997; 350: 1284-1287.
33. Aisu T, Raviglione M C, Van Praag E, et al. Preventive chemotherapy for HIV-associated tuberculosis in Uganda: an operational assessment at a voluntary counseling and testing centre. AIDS 1995; 9: 267-273.
34. Espinal M A, Reingold A L, Koenig E, Lavandera M, Sanchez S. Screening for active tuberculosis in HIV testing centre. Lancet 1995; 345: 890-893.
35. Desormeaux J, Johnson M P, Coberly J S, et al. Widespread HIV counseling and testing linked to a community-based tuberculosis control programme in a high risk population. Bull Pan Am Health Organ 1996; 120: 463-471.
36. Nunn P, Mungai M, Nyamwaya J, et al. The effect of human immunodeficiency virus type 1 on the infectiousness of tuberculosis. Tubercle Lung Dis 1994; 75: 25-32.
37. Whalen CC, Johnson J L, Okwera A, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. N Engl J Med 1997; 337: 801-808.
38. De Cock K M, Grant A, Porter J D H. Preventive therapy for tuberculosis in HIV-infected persons: international recommendations, research, and practice. Lancet 1995; 345: 833-836.
39. O'Brien R J, Perriens J H. Preventive therapy for tuberculosis in HIV infection: the promise and the reality. AIDS 1995; 9: 665-673.
40. Pape J W, Jean S S, Ho J, Haffner A, Johnson W D Jr. Effect of isoniazid on the natural history of HIV infection in Haiti. Lancet 1993; 342: 268-272.
41. Halsey N A, Coberly J S, Desoimeaux J, et al. Randomized trial of isoniazid versus rifampicin and pyrazinamide for the prevention of tuberculosis in HIV-1 infection. Lancet 1998; 331: 786-792.
42. World Health Organization. Tuberculosis preventive therapy in HIV-infected individuals. Wkly Epidemiol Rec 1993; 68: 361-368.
43. Frieden T R, Woodley C L, Crawford J T, Lew D, Dooley S M. The molecular epidemiology of tuberculosis in New York City: the importance of nosocomial transmission and laboratory error. Tubercle Lung Dis 1996; 77: 407-413.
44. Sidibe K, Zuber P, Wiktor S Z, et al. Tuberculin skin test reactivity among health care workers and level of exposure to tuberculosis patients in Abidjan, Côte d'Ivoire, Int J Tuberc Lung Dis 1997; 1 (Suppl): S27.
45. Harries A D, Kamenya A, Namarika D, et al. Delays in diagnosis and treatment of smear-positive tuberculosis and the incidence of tuberculosis in hospital nurses in Blantyre, Malawi. Trans Roy Soc Trop Med Hyg 1997; 91: 15-17.
46. Harries A D, Maher D, Nunn P. Practical and affordable measures for the protection of health care workers from tuberculosis in low-income countries. Bull World Health Organ 1997; 75: 477-489.
47. Chaulk C P, Moore-Rice K, Rizzo R, Chaisson R E. Eleven years of community-based direct y observed therapy for tuberculosis. JAMA 1995; 274: 945-951.
48. Graham N M, Galai N, Nelson K E, et al. Effect of isoniazid chemoprophylaxis on HIV-related mycobacterial disease. Arch Intern Med 1996; 156: 889-894.
49. Hanson M L, Comstock G W, Haley C E. Community isoniazid prophylaxis program in an underdeveloped area of Alaska. Public Health Reports 1967; 82: 1045-1056.
50. Comstock G W. Isoniazid prophylaxis in an underdeveloped area. Am Rev Respir Dis 1962; 86: 810-822.
51. Cohn D L, O'Brien R J. The use of restriction fragment length polymorphism (RFLP) analysis for epidemiological studies of tuberculosis in developing countries. Int J Tuberc Lung Dis 1998; 2: 16-26.
52. CDC. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health care facilities, 1994. MMWR 1994; 43 (RR-13): 1-132.
53. Abouya L, Coulibaly I M, Wiktor S Z, et al. The Côte d'Ivoire national HIV counseling and testing program for tuberculosis patients: implementation and analysis of epidemiologic data. AIDS 1998; 12: 505-512.
54. Gilks C F, Katabira E, De Cock K M. The challenge of providing effective care for HIV/AIDS in Africa. AIDS 1997; 11 (Suppl B): S99-S106.